Observational Study of Meloxicam in Any Labeled Indication

Evaluation on the amelioration of symptom intensity of the indication and to evaluate drug tolerability.

Completed

Looking for future studies?

Key information

Conditions

Arthritis, Rheumatoid Arthritis Autoimmune Diseases Connective Tissue Diseases Immune System Diseases Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Skin and Connective Tissue Diseases

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients according to the physicians medical criteria on the labeled indications for Meloxicam

Exclusion criteria

none

Treatment and study plan

Meloxicam

Drug

tablets or injectable solution

Primary outcomes

Change in assessment of intensity of pain on a 4-point verbal rating scale

Time frame: up to 1 year
Assessment of tolerability on a 4-point scale

Time frame: up to 1 year

Secondary outcomes

Number of patients with adverse events

Time frame: up to 1 year

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

Programa de Experiencia Therapéutica Personalizada (Personalized Therapeutic Experience Program)

Important dates

Study start: 2001
Primary completion: 2001
First posted: Jul 8, 2014
Registry last updated: Oct 29, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed